CHU Dual-Energy Ablation in Ventricular Arrhythmia

Enrolling by invitation · Not applicable

Conditions studied: Premature Ventricular Contractions, Ventricular Tachycardia

In brief

The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.

Key facts

Study ID

NCT07503769

Run by

Shanghai MicroPort EP MedTech Co., Ltd.

People needed

10

Starts

2026-02-03

Expected to finish

2026-10-31

Last updated by the study team

2026-03-31

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient age ≥ 18 years and ≤ 75 years；
• Clinically diagnosed with tachyarrhythmia, specifically idiopathic ventricular arrhythmia；
• Recurrent disease with obvious symptoms prior to enrollment;
• Failure to respond to or intolerance of at least one antiarrhythmic drug;
• Fully understand the treatment plan, voluntarily sign the informed consent form, and agree to undergo the examinations, procedures and follow-up as required by the protocol.

You may not qualify if…

• Left ventricular ejection fraction (LVEF) ≤ 40%
• History of ventricular flutter or ventricular fibrillation
• Diagnosis of long QT syndrome or arrhythmogenic cardiomyopathy
• Presence of structural heart disease or organic heart disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, rheumatic heart disease, and congenital heart disease
• Previous atrial septal repair or atrial myxoma
• Carrying an active implantable device in the body (e.g., cardiac pacemaker, ICD, etc.)
• NYHA functional class Ⅲ-Ⅳ
• Patients with documented cerebrovascular disease within the past 6 months (including cerebral hemorrhage, stroke, transient ischemic attack)
• Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting, prosthetic valve replacement or repair, atrial or ventricular incision)
• Patients with acute or severe systemic infection
• Patients with severe hepatic or renal disease, malignant tumor, or end-stage disease, who, in the investigator's judgment, may interfere with the treatment, evaluation, or compliance of this trial
• Patients with significant bleeding tendency, hypercoagulable state, or severe hematological disorders
• Patients who have participated in or are currently participating in other clinical trials within 3 months prior to enrollment
• Patients with other conditions deemed inappropriate for participation in this trial by the investigator.

Where it is running

• The First Affiliated Hospital of Ningbo University — Ningbo, Zhejiang, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.